407 related articles for article (PubMed ID: 25845418)
21. Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells.
Aranovich A; Liu Q; Collins T; Geng F; Dixit S; Leber B; Andrews DW
Mol Cell; 2012 Mar; 45(6):754-63. PubMed ID: 22464442
[TBL] [Abstract][Full Text] [Related]
22. Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia.
Gaudette BT; Dwivedi B; Chitta KS; Poulain S; Powell D; Vertino P; Leleu X; Lonial S; Chanan-Khan AA; Kowalski J; Boise LH
Oncogene; 2016 Jan; 35(4):479-90. PubMed ID: 25893290
[TBL] [Abstract][Full Text] [Related]
23. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.
Will B; Siddiqi T; Jordà MA; Shimamura T; Luptakova K; Staber PB; Costa DB; Steidl U; Tenen DG; Kobayashi S
Blood; 2010 Apr; 115(14):2901-9. PubMed ID: 20160166
[TBL] [Abstract][Full Text] [Related]
24. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.
Yecies D; Carlson NE; Deng J; Letai A
Blood; 2010 Apr; 115(16):3304-13. PubMed ID: 20197552
[TBL] [Abstract][Full Text] [Related]
25. 2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines.
Zagorodna O; Martin SM; Rutkowski DT; Kuwana T; Spitz DR; Knudson CM
Oncogene; 2012 May; 31(22):2738-49. PubMed ID: 21986940
[TBL] [Abstract][Full Text] [Related]
26. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.
Pandey MK; Gowda K; Doi K; Sharma AK; Wang HG; Amin S
PLoS One; 2013; 8(11):e78570. PubMed ID: 24223823
[TBL] [Abstract][Full Text] [Related]
27. Bim deficiency leads to exacerbation and prolongation of joint inflammation in experimental arthritis.
Scatizzi JC; Bickel E; Hutcheson J; Haines GK; Perlman H
Arthritis Rheum; 2006 Oct; 54(10):3182-93. PubMed ID: 17009248
[TBL] [Abstract][Full Text] [Related]
28. Bcl-2 allows effector and memory CD8+ T cells to tolerate higher expression of Bim.
Kurtulus S; Tripathi P; Moreno-Fernandez ME; Sholl A; Katz JD; Grimes HL; Hildeman DA
J Immunol; 2011 May; 186(10):5729-37. PubMed ID: 21451108
[TBL] [Abstract][Full Text] [Related]
29. Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Lheureux S; N'Diaye M; Blanc-Fournier C; Dugué AE; Clarisse B; Dutoit S; Giffard F; Abeilard E; Briand M; Labiche A; Grellard JM; Crouet H; Martin S; Joly F; Poulain L
Int J Cancer; 2015 Mar; 136(5):E340-50. PubMed ID: 25066666
[TBL] [Abstract][Full Text] [Related]
30. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.
Coloff JL; Macintyre AN; Nichols AG; Liu T; Gallo CA; Plas DR; Rathmell JC
Cancer Res; 2011 Aug; 71(15):5204-13. PubMed ID: 21670080
[TBL] [Abstract][Full Text] [Related]
31. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
[TBL] [Abstract][Full Text] [Related]
32. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
33. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.
Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A
Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110
[TBL] [Abstract][Full Text] [Related]
34. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
35. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
[TBL] [Abstract][Full Text] [Related]
36. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.
Kline MP; Rajkumar SV; Timm MM; Kimlinger TK; Haug JL; Lust JA; Greipp PR; Kumar S
Leukemia; 2007 Jul; 21(7):1549-60. PubMed ID: 17460700
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W
Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354
[TBL] [Abstract][Full Text] [Related]
38. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
Karlberg M; Ekoff M; Huang DC; Mustonen P; Harvima IT; Nilsson G
J Immunol; 2010 Aug; 185(4):2555-62. PubMed ID: 20639495
[TBL] [Abstract][Full Text] [Related]
39. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
40. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
Albershardt TC; Salerni BL; Soderquist RS; Bates DJ; Pletnev AA; Kisselev AF; Eastman A
J Biol Chem; 2011 Jul; 286(28):24882-95. PubMed ID: 21628457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]